These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 21339909)
1. ACE up the sleeve - are vascular patients medically optimized? Coveney AP; O'Brien GC; Fulton GJ Vasc Health Risk Manag; 2011 Jan; 7():15-21. PubMed ID: 21339909 [TBL] [Abstract][Full Text] [Related]
2. Effects on Mortality and Cardiovascular Events of Adherence to Guideline-Recommended Therapy 4 Years after Lower Extremity Arterial Revascularization. Thiney M; Della Schiava N; Ecochard R; Feugier P; Lermusiaux P; Millon A; Long A Ann Vasc Surg; 2018 Oct; 52():138-146. PubMed ID: 29777848 [TBL] [Abstract][Full Text] [Related]
3. How Admission to a Vascular Surgery Department Improves Medical Treatment in Patients with Lower Extremity Peripheral Arterial Disease. Thiney M; Della Schiava N; Feugier P; Lermusiaux P; Ninet J; Millon A; Long A Ann Vasc Surg; 2017 Apr; 40():85-93. PubMed ID: 27908822 [TBL] [Abstract][Full Text] [Related]
4. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. Lee HY; Cooke CE; Robertson TA J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049 [TBL] [Abstract][Full Text] [Related]
5. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar. El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397 [TBL] [Abstract][Full Text] [Related]
6. Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India. Sharma KK; Gupta R; Agrawal A; Roy S; Kasliwal A; Bana A; Tongia RK; Deedwania PC Vasc Health Risk Manag; 2009; 5():1007-14. PubMed ID: 19997570 [TBL] [Abstract][Full Text] [Related]
8. Prevalence of use of antiplatelet drugs, beta blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in older patients with coronary artery disease in an academic nursing home. Joseph J; Koka M; Aronow WS J Am Med Dir Assoc; 2008 Feb; 9(2):124-7. PubMed ID: 18261706 [TBL] [Abstract][Full Text] [Related]
9. Vascular quality of care pilot study: how admission to a vascular surgery service affects evidence-based pharmacologic risk factor modification in patients with lower extremity peripheral arterial disease. Steenhof N; Le Piane F; Leblanc K; Eisenberg NR; Kwan Y; Malmberg C; Papadopoulos A; Roche-Nagle G Vasc Health Risk Manag; 2014; 10():333-40. PubMed ID: 24940068 [TBL] [Abstract][Full Text] [Related]
10. The use of secondary medical prevention after primary vascular reconstruction: studies on usage and effectiveness. Høgh AL Dan Med J; 2012 Sep; 59(9):B4514. PubMed ID: 22951205 [TBL] [Abstract][Full Text] [Related]
11. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction. Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001 [TBL] [Abstract][Full Text] [Related]
13. Optimal medical management of peripheral arterial disease. Rice TW; Lumsden AB Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725 [TBL] [Abstract][Full Text] [Related]
14. Use of guideline-recommended therapies for heart failure in the Medicare population. DiMartino LD; Shea AM; Hernandez AF; Curtis LH Clin Cardiol; 2010 Jul; 33(7):400-5. PubMed ID: 20641116 [TBL] [Abstract][Full Text] [Related]
15. Five-year follow-up of drug utilization for secondary prevention in coronary artery disease. Apikoglu Rabus S; Izzettin FV; Sancar M; Karakaya O; Kargin R; Yakut C Pharm World Sci; 2008 Dec; 30(6):753-8. PubMed ID: 18563622 [TBL] [Abstract][Full Text] [Related]
16. How optimal is the medical management of patients prior to major reconstructive vascular surgery? The results of a cross-sectional study. Marshall C; Lin PH; Huynh TT; Kougias P Vasc Endovascular Surg; 2009; 43(3):238-43. PubMed ID: 19190039 [TBL] [Abstract][Full Text] [Related]
17. Medical Therapy Utilization and Long-Term Outcomes Following Percutaneous Coronary Intervention: Five-Year Results From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program. Xie JX; Gunzburger EC; Kaun L; Plomondon ME; Barón AE; Waldo SW; Virani SS; Maddox TM; Mavromatis K Circ Cardiovasc Qual Outcomes; 2019 Nov; 12(11):e005455. PubMed ID: 31665896 [TBL] [Abstract][Full Text] [Related]
18. Optimizing prevention and guideline-concordant care in Montenegro. Knežević B; Musić L; Batrićević G; Bošković A; Bulatović N; Nenezić A; Vujović J; Kalezić M Int J Cardiol; 2016 Aug; 217 Suppl():S32-6. PubMed ID: 27381861 [TBL] [Abstract][Full Text] [Related]
19. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction. Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological treatment after acute myocardial infarction from 2001 to 2006: a survey in Italian primary care. Filippi A; D'Ambrosio G; Giustini SE; Pecchioli S; Mazzaglia G; Cricelli C J Cardiovasc Med (Hagerstown); 2009 Sep; 10(9):714-8. PubMed ID: 19465867 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]